cu-cpt17e

Description: CU-CPT17e is a multi-TLR(Toll-like receptor) agonist that activates TLR3, TLR8, and TLR9. Therapies based on activation of multiple Toll-like receptors (TLRs) may offer superior therapeutic profiles than that of single TLR activation. CU-CPT17e was identified from a cell-based high-throughput screening of a small-molecule library based on TLR3-mediated NF-kappaB activation. Biochemical studies demonstrated that CU-CPT17e could induce a strong immune response via the production of various cytokines in human monocytic THP-1 cells. Furthermore, CU-CPT17e inhibited the proliferation of HeLa cancer cells by triggering apoptosis and arresting the cell cycle at the S phase. These results showcase potential therapeutic applications of CU-CPT17e in both vaccine adjuvants and anticancer therapies based on multi-TLR activation.

References: J Med Chem. 2017 Jun 22; 60(12):5029-5044. Nat Chem Biol. 2018 Jan; 14(1):58-64.

Related CAS#:2165340-32-7 (CU-CPT-9b); 2162962-69-6 (CU-CPT-9a); 125079-83-6 (CU-CPT-8m)